The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Rachel Thrasher, Research Fellow at the Global Development Policy Center in Boston, says this time is different and the TRIPS Council knows it - the COVID-19 vaccine needs to be freely accessible to all countries.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
New data from the Oxford COVID vaccine trial shows that the UK antidote is working well at Phase two, with defining percentages expected after Phase Three is complete.
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
European Public Health Association Executive Director, Dineke Zeegers Paget examines COVID-19 as a societal issue, not just a pandemic and argues that solidarity here is needed the most.
While the US and UK sealed their BioNTech and Pfizer vaccine deals within 24 hours of the new results, the European Commission took 3 days longer to secure their larger order of 300 million doses.
Yesterday, at 6:45am in the US, the Pfizer vaccine was revealed to be over 90% effective - so when will the successful drug be available for the UK to use?
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group considers how the standard of healthcare for patients with diabetes is impacted by COVID-19.
Over 12 US Immigration and Customs Enforcement (ICE) detention centres had multiple outbreaks of infectious disease - due to withholding vaccines for adult and child migrants.
